Shots:

• The company has initiated the dosing in the P-I clinical study to evaluate the PK, safety, and tolerability of BAT6026 as monothx. in patients with advanced solid tumor
• The objectives of the study are to determine MTD, PK, and preliminary anti-tumor activity while disease-specific expansion cohorts will be enrolled at the maximally tolerated or biologically relevant dose
• BAT6026 is an agonist mAb targeting OX40 in cancer patient & was developed using Bio-Thera’s proprietary IDEAL platform. The company plans to advance the therapy in combination with BAT1308 to treat cancer

Ref: Businesswire | Image: Biothera